Company intelligence / Profile preview

Mist Pharmaceuticals

Montreal, Quebec, Canada

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Milestone Pharmaceuticals received FDA approval on December 17, 2025, for CARDAMYST (etripamil) nasal spray for conversion of acute symptomatic PSVT in adults, marking the first FDA-approved PSVT treatment in 30+ years[5]. Phase 3 RAPID trial data demonstrated 64% conversion at 30 minutes versus 31% with placebo (HR=2.62; p<0.001) and a median time to conversion of 17 versus 54 minutes[5]. The company is advancing Phase 3 development (ReVeRA-301) for AFib-RVR indication and Phase 1/2 studies in pediatric PSVT patients[2].

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Aptar (delivery device partner for CARDAMYST)RTW Investments (royalty agreement partner)

Beyond the preview

Go deeper on Mist Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mist Pharmaceuticals.

Explore the full profile